Skip to main content
Article thumbnail
Location of Repository

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

By R Rosso, C Bernardini, B Bruzzone, G Secondo, G Icardi, C Viscoli and A Di Biagio


Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons. We report the case of a 15-year-old Caucasian male, with vertically acquired HIV-1 infection, who failed several lines of antiretroviral therapy and was successfully treated with darunavir/ritonavir and etravirine

Topics: Case Report
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. Accepted: February 3,
  2. (2008). An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. Antivir Ther.
  3. (2008). Intelence Prescribing Information.
  4. (2008). New resistance score for tipranavir. AIDS Rev.
  5. (2007). Paediatric EuropeanNetwork for theTreatment ofAIDS(PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS.
  6. (2007). Pharmacokinetics and antiretroviral response to Darunavir/ritonavir and Etravirine combination in patients with high-level viral resistance. AIDS.
  7. (2007). Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother.
  8. (2008). Review of HIV Antiretroviral Drug Resistance. Pediatr Infect Dis J.
  9. (2007). study group. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS.
  10. (2007). Woodfall B; DUET1 study group. Efficacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, doubleblind, placebo-controlled-trial. Lancet.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.